Media centre
Medical and surgical management of metastatic bowel cancer (mCRC) has improved over recent years, but treatments for mCRC patients that deliver even modest incremental life-extending benefits remain limited compared to those available for patients with other common cancers.
With just over one in ten (13.4%) mCRC patients surviving five years after diagnosis, there is a clear clinical need for new treatment options.
- Details
Bowel Cancer Australia is pleased to have been selected as a charity beneficiary of the new Ritchies Community Benefit Program.
Donating a percentage of the money spent by registered customers to their nominated charity, including Bowel cancer Australia, the Ritchies Community Benefit Program now has an App for both IOS and Android smart devices.
- Details
In recognition of World mCRC Day, Marty has joined Bowel Cancer Australia and our international partners to raise awareness about metastatic colorectal (bowel) cancer.
In mid-December 2019, I was diagnosed with Stage 4 metastatic bowel cancer, at age 42.
It took about 6 weeks to get myself into a frame of mind to deal with it.
- Details
- Details
“The goal was to look at bowel cancer in a holistic way by taking information from genes, microbes and epigenetic data,” Zoe said.
- Details
Evidence has long suggested an association between mouth bacteria that enters the bloodstream via bleeding gums and serious infections of the brain, liver, and heart, as well as preterm birth in pregnant women.
The presence of the bacterium, known as ‘fusobacterium nucleatum’, has also been shown to be very high in bowel tumours.
- Details
Yet the latest National Bowel Cancer Screening Program (NBCSP) Report released today by the AIHW reveals participation rates continue to hover at 42.4% and colonoscopy wait times for those who receive a positive screen far exceed the ‘desirable’ 30 days.ii
- Details
- Details
- Details
